In this educational rheumatology video, physician assistant Lindsay Tom, PA-C, from the Northern Virginia Center for Arthritis, provides a clear and clinically relevant overview of CD64, also known as FC gamma receptor I, and its role in immune system function. The discussion explores how CD64 is expressed on myeloid lineage cells such as monocytes, macrophages, and dendritic cells, and how it contributes to innate immunity by binding IgG antibodies and triggering phagocytosis and pro-inflammatory cytokine release, including TNF-α. The video also explains CD64’s role in adaptive immunity through antigen processing and presentation to T cells, leading to immune activation and immunologic memory. Importantly, this overview highlights how dysregulated or excessive CD64 activation may contribute to chronic inflammation, tissue damage, and antibody-mediated autoimmune diseases—making it a key concept for clinicians managing inflammatory and rheumatic conditions. This video is part of ongoing educational content designed for advanced practice providers seeking a deeper understanding of immunologic pathways relevant to rheumatology care.

In this short video, pediatric rheumatology advanced practice providers Brandon Ko, APRN, DNP, C-PNP, and Brandi Goble, PNP, share their personal journeys into pediatric rheumatology and discuss the critical role APPs play in expanding access to care—especially in rural and underserved communities. They highlight the challenges of entering a highly specialized field with limited formal training, the importance of mentorship, and how RhAPP and the Step Up to Rheumatology curriculum have helped build community, education, and confidence for pediatric rheumatology APPs nationwide. This conversation offers insight into workforce gaps, real-world training pathways, and the growing impact of APPs in pediatric rheumatology care.

In this video, Audrey Gibson, PA-C, a rheumatology physician assistant with nearly two decades of clinical experience, breaks down the unique dual mechanism of action of guselkumab and its role in targeting IL-23–driven inflammation. The discussion explores how this fully human monoclonal antibody selectively binds the IL-23 p19 subunit to inhibit downstream inflammatory signaling, while also engaging CD64 on inflammatory monocytes through its Fc region, addressing IL-23 at its source. Designed to clarify the science behind dual-acting IL-23 inhibition, this overview provides practical insight for clinicians managing immune-mediated rheumatic diseases and highlights emerging therapeutic strategies in modern rheumatology care.